Adolescent immunisation: The next big thing?

Archives of Disease in Childhood

Volumn 96, Issue 6, 2011, Pages 497-499

  Finn, Adam ^a   Clarke, Ed ^a   Mytton, Julie ^b  

^a UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

^b NATIONAL HEALTH SERVICE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS VACCINE; HEPATITIS B VACCINE; MENINGOCOCCUS VACCINE; WART VIRUS VACCINE;

ANTIBODY BLOOD LEVEL; AUTISM; BORDETELLA PERTUSSIS; CELLULAR IMMUNITY; CHICKENPOX; CHILD HEALTH CARE; CHLAMYDIASIS; CUBA; DRUG MARKETING; EDITORIAL; FRANCE; GERMANY; HEALTH INSURANCE; HEPATITIS B; HERPES SIMPLEX; HUMAN; INFECTION CONTROL; INFECTION RATE; MEASLES; MENINGOCOCCOSIS; MUMPS; NEW ZEALAND; PARENTAL CONSENT; PERTUSSIS; PRESCHOOL CHILD; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RUBELLA; SCHOOL HEALTH NURSING; SCHOOL HEALTH SERVICE; SEXUALLY TRANSMITTED DISEASE; UNITED KINGDOM; UNITED STATES; VACCINATION; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADOLESCENT HEALTH SERVICES; CHILD; FEMALE; GREAT BRITAIN; HUMANS; IMMUNIZATION PROGRAMS; IMMUNIZATION SCHEDULE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES;

EID: 79951871167     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.2010.192070     Document Type: Editorial

References (36)

1. O'Dowd A. Teenager who died after having HPV vaccine had a malignant chest tumour. BMJ 2009;339:b4032.
2. Department of Health. Annual HPV Vaccine Uptake Rate in England: 2008/2009. 2010.
3. Brabin L, Roberts SA, Stretch R, et al. Uptake of first two doses of human papillomavirus vaccine by adolescent schoolgirls in Manchester: prospective cohort study. BMJ 2008;336:1056-8. (Pubitemid 351692248)
4. Brabin L, Roberts SA, Stretch R, et al. A survey of adolescent experiences of human papillomavirus vaccination in the Manchester study. Br J Cancer 2009;101:1502-4.
5. Brown EC. Human papillomavirus vaccine: Some issues around consent remain unresolved. BMJ 2008;336:1146. (Pubitemid 351809263)
6. Tanne JH. Questions over human papillomavirus vaccine in the US and Australia. BMJ 2007;334:1182-3.
7. Siegrist CA, Lewis EM, Eskola J, et al. Human papilloma virus immunization in adolescent and young adults: a cohort study to illustrate what events might be mistaken for adverse reactions. Pediatr Infect Dis J 2007;26:979-84. (Pubitemid 350287577)
8. The NHS Information Centre. NHS Immunisation Statistics 2008-2009 Version 1.0. 2009.
9. Forsyth KD, Wirsing von Konig CH, Tan T, et al. Prevention of pertussis: recommendations derived from the second Global Pertussis Initiative roundtable meeting. Vaccine 2007;25:2634-42. (Pubitemid 46400927)
10. Forsyth KD, Campins-Marti M, Caro J, et al. New pertussis vaccination strategies beyond infancy: recommendations by the global pertussis initiative. Clin Infect Dis 2004;39:1802-9. (Pubitemid 39657260)
11. Schellekens J, von König CH, Gardner P. Pertussis sources of infection and routes of transmission in the vaccination era. Pediatr Infect Dis J 2005;24:S19-24.
12. Marra F, Cloutier K, Oteng B, et al. Effectiveness and cost effectiveness of human papillomavirus vaccine: a systematic review. Pharmacoeconomics 2009;27:127-47.
13. Expanded programme on immunization. Global Advisory Group-part I. Wkly Epidemiol Rec 1992;67:11-15.
14. Finney M, Vaughan T, Taylor S, et al. Characterization of the key antigenic components and pre-clinical immune responses to a meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles. Hum Vaccin 2008;4:23-30. (Pubitemid 351785257)
15. Trotter CL, Gay NJ, Edmunds WJ. The natural history of meningococcal carriage and disease. Epidemiol Infect 2006;134:556-66.
16. Sierra GV, Campa HC, Varcacel NM, et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann 1991;14:195-207; discussion 208-10.
17. Vaughan AT, Gorringe A, Davenport V, et al. Absence of mucosal immunity in the human upper respiratory tract to the commensal bacteria Neisseria lactamica but not pathogenic Neisseria meningitidis during the peak age of nasopharyngeal carriage. J Immunol 2009;182:2231-40.
18. Lennon D, Jackson C, Wong S, et al. Fast tracking the vaccine licensure process to control an epidemic of serogroup B meningococcal disease in New Zealand. Clin Infect Dis 2009;49:597-605.
19. Lucidarme J, Comanducci M, Findlow J, et al. Characterisation of fHbp, nhba (gna2132), nadA, porA and Sequence Type in group B meningococcal case isolates collected in England and Wales during January 2008, and potential coverage of an investigational group B meningococcal vaccine. Clin Vaccine Immunol 2010;(In Press).
20. Campbell H, Borrow R, Salisbury D, et al. Meningococcal C conjugate vaccine: the experience in England and Wales. Vaccine 2009;27(Suppl 2):B20-9.
21. Borrow R, Andrews N, Findlow H, et al. Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and Haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine. Clin Vaccine Immunol 2010;17:154-9.
22. Pollard AJ, Perrett KP, Beverley PC. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat Rev Immunol 2009;9:213-20.
23. Rijkers GT, Vermeer-de Bondt PE, Spanjaard L, et al. Return of Haemophilus influenzae type b infections. Lancet 2003;361:1563-4. (Pubitemid 36566360)
24. Snape MD, Kelly DF, Lewis S, et al. Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study. BMJ 2008;336:1487-91. (Pubitemid 351977021)
25. Gasparini R, Conversano M, Bona G, et al. Randomized trial on the safety, tolerability, and immunogenicity of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, administered concomitantly with a combined tetanus, reduced diphtheria, and acellular pertussis vaccine in adolescents and young adults. Clin Vaccine Immunol 2010;17:537-44.
26. Ostergaard L, Lebacq E, Poolman J, et al. Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15-25 years. Vaccine 2009;27:161-8.
27. Joint Committee on Vaccination and Immunisation. Statement of Varicella and Herpes Zoster Vaccines. 2010.
28. Thomas SL, Wheeler JG, Hall AJ. Contacts with varicella or with children and protection against herpes zoster in adults: a case-control study. Lancet 2002;360:678-82. (Pubitemid 35232336)
29. Brisson M, Gay NJ, Edmunds WJ, et al. Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox. Vaccine 2002;20:2500-7. (Pubitemid 34615588)
30. Boyaka PN, Wright PF, Marinaro M, et al. Human nasopharyngeal-associated lymphoreticular tissues. Functional analysis of subepithelial and intraepithelial B and T cells from adenoids and tonsils. Am J Pathol 2000;157:2023-35.
31. Holmes CN. Predictive value of a history of varicella infection. Can Fam Physician 2005;51:60-5. (Pubitemid 40202165)
32. Christiansen G, Birkelund S. Is a Chlamydia vaccine a reality? Best Pract Res Clin Obstet Gynaecol 2002;16:889-900.
33. Rupp R, Bernstein DI. The potential impact of a prophylactic herpes simplex vaccine. Expert Opin Emerg Drugs 2008;13:41-52. (Pubitemid 351448701)
34. Stanberry LR, Spruance SL, Cunningham AL, et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med 2002;347:1652-61. (Pubitemid 35340783)
35. Health Protection Agency. Laboratory confirmed cases of measles, mumps and rubella, England and Wales: April to June 2005. CDR Weekly Report 2005;15:16-18.
36. Chief Medical Officer. PL CMO (2008)5: The MMR Vaccination Catch-Up Programme. 2008.